TodorNedeltchevDentchevMD

Oncology • Grand Forks, ND

Physician

Join to view full profile

Are you Dr. Dentchev?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 39 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
960 S Columbia Rd Altru Cancer Center
Grand Forks, ND 58201
Phone+1 701-780-5400

Fax+1 701-780-6416
Is this information wrong?

Summary

Dr. Todor Dentchev, MD is an oncologist in Grand Forks, North Dakota. He is currently licensed to practice medicine in North Dakota, Minnesota, and Kansas. He is affiliated with Altru Health System and Fargo VA Medical Center.

Education & Training

Brooklyn Hospital CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Brooklyn Hospital CenterResidency, Internal Medicine, 1994 - 1997
Medical University of Sofia FOMClass of 1984

Certifications & Licensure

MN State Medical License 2012 - 2024
ND State Medical License 2001 - 2024
MO State Medical License Active through 2013
KS State Medical License 2011 - 2012
ME State Medical License Active through 2003
FL State Medical License 2001 - 2002

Clinical Trials

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2

Publications & Presentations

PubMed

36 citations
A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.
Deirdre R. Pachman, Travis J. Dockter, Patricia J. Zekan, Briant Fruth, Kathryn J. Ruddy, Lauren E. Ta, Jacqueline M. Lafky, Todor Dentchev, Nguyet A. Le-Lindqwister, ...> ;Supportive Care in Cancer. 2017 May 27
137 citations
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Axel Grothey, Daniel A. Nikcevich, Jeff A. Sloan, John W. Kugler, Peter T. Silberstein, Todor Dentchev, Donald B. Wender, Paul J. Novotny, Umesh Chitaley, Steven R. Al...> ;Journal of Clinical Oncology. 2011 Feb 1
16 citations
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
Ann E. Kearns, Donald W. Northfelt, Amylou C. Dueck, Pamela J. Atherton, Shaker R. Dakhil, Kendrith M. Rowland, Jyotsna Fuloria, Patrick J. Flynn, Todor Dentchev, Char...> ;Supportive Care in Cancer. 2010 Mar 1
51 citations
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National...
Steven R. Alberts, Mark S. Roh, Michelle R. Mahoney, Michael J. O'Connell, David M. Nagorney, Lawrence Wagman, Thomas C. Smyrk, Timothy L. Weiland, Lily Lau Lai, Roder...> ;Journal of Clinical Oncology. 2010 Feb 10
37 citations
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastat...
E. A. Perez, David W. Hillman, Todor Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, Tom R. Fitch, Heshan Liu, David L. Graham, S. P. Kahanic, H. M. Gross, Tejal Pate...> ;Annals of Oncology. 2010 Feb 1
Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled ...
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Windschilt HE, Zhao X, Loprinzi CL> ;J. Clin. Oncol.. 2009-05-20
65 citations
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Stephanie L. Hines, Betty A. Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve R. Alberts, Heshan Liu, S. P. Kahanic, Mi...> ;Breast Cancer Research and Treatment. 2009 Feb 12
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-con...
Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL> ;J. Clin. Oncol.. 2008-05-20
N03CC-a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast ca...
Mincey BA, Dentchev T, Sloan JA, Hines SL, Perez EA, Johnson DB, Schaefer PL, Liu H, Kahanic SP, Loprinzi CL> ;J. Clin. Oncol.. 2008-05-20
37 citations
Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer
David P. Steensma, Roy Molina, Jeff A. Sloan, Daniel A. Nikcevich, Paul L. Schaefer, Kendrith M. Rowland, Todor Dentchev, Paul J. Novotny, Loren K. Tschetter, Steven R...> ;Journal of Clinical Oncology. 2006 Mar 1
A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group ...
Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Tschetter LK, Novotny PJ, Loprinzi CL> ;J. Clin. Oncol.. 2005-06-01
A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC).
Johnson EA, Marks RS, Mandrekar S, Hillman S, Mailliard J, Dentchev T, Reuter N, Jett J, Perez EA> ;J. Clin. Oncol.. 2005-06-01
Join now to see all

Hospital Affiliations

Altru Health SystemGrand Forks, North Dakota
Fargo VA Medical CenterFargo, North Dakota